BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19690030)

  • 1. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors.
    Herrmann K; Eckel F; Schmidt S; Scheidhauer K; Krause BJ; Kleeff J; Schuster T; Wester HJ; Friess H; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2008 Sep; 49(9):1437-44. PubMed ID: 18703612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of proliferation in malignant lymphoma.
    Buck AK; Bommer M; Stilgenbauer S; Juweid M; Glatting G; Schirrmeister H; Mattfeldt T; Tepsic D; Bunjes D; Mottaghy FM; Krause BJ; Neumaier B; Döhner H; Möller P; Reske SN
    Cancer Res; 2006 Nov; 66(22):11055-61. PubMed ID: 17108145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using
    Sharma R; Inglese M; Dubash S; Lu H; Pinato DJ; Sanghera C; Patel N; Chung A; Tait PD; Mauri F; Crum WR; Barwick TD; Aboagye EO
    J Nucl Med; 2020 Dec; 61(12):1743-1748. PubMed ID: 32513905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
    Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
    J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.
    Choi SJ; Kim JS; Kim JH; Oh SJ; Lee JG; Kim CJ; Ra YS; Yeo JS; Ryu JS; Moon DH
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):653-9. PubMed ID: 15711980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
    Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
    J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.